期刊文献+

欧盟成员国植物药产品审评现状分析及启示 被引量:6

Analysis on current status of assessment on herbal medicinal products in EU and its enlightenment
原文传递
导出
摘要 欧盟的植物药发展处于世界领先水平,开拓中成药的欧盟市场对中药国际化具有重要意义,然而当前我国中成药在欧盟的注册面临诸多挑战。首先介绍中成药在欧盟获得药品身份的上市路径,然后对欧盟成员国植物药产品审评总体状况、获批药品的组分特点、植物药专论的应用以及主要适应症等方面进行分析,最终提出我国中成药产品在欧盟通过注册的相关建议。 It is of great importance to bring proprietary Chinese medicines to EU as its herbal medicinal product is world-leading, yet the current status for registrations from China is full of challenges. The routes for registration of herbal medicinal products are introduced at first and then the current registration status on the overall assessment of the products, the characteristics of combinations, the utilization of EU monograph and main indications are analyzed. Suggestions on registering proprietary Chinese medicines are made in the end.
出处 《中草药》 CAS CSCD 北大核心 2016年第24期4494-4498,共5页 Chinese Traditional and Herbal Drugs
基金 国家中医药管理局基金资助项目(SATCM-2014-FZ01) 教育部哲学社会科学研究重大课题攻关项目(14JZD025)
关键词 2004/24/EC指令 植物药 中成药 欧盟植物药专论 植物药注册 directive 2004/24/EC herbal drug Chinese patent drug EU monograph registration of herbal drug
  • 相关文献

参考文献4

二级参考文献23

  • 1李洁.2007国际风险投资趋势及江苏风险投资发展对策[J].江苏商论,2007(4):154-155. 被引量:1
  • 2Kaplinsky.Spreading the gains from globaohsation: what can be learnedfrom value chain analysis [J]. Join.hal of Development Studies,2000,37(2) ,117-146.
  • 3张继焦.价值链管理[M].北京:中国物价出版社,2001..
  • 4迈克尔·波特.国家竞争优势[M].北京:华夏出版社,2002.
  • 5Williamson E M, Lorene A, Booker A, et al. The rise oftraditional Chinese medicine and its materia medica: A comparison of the frequency and safety of materials and species used in Europe and China [J]. J Ethnopharmacol, 2013, 149(2): 453-462.
  • 6Steirahoff B. The first HMPC community herbal monographs [J]. Phytomedicine, 2006, 13(5): 378-379.
  • 7Committee on Herbal Medicinal Products. Guideline on the assessment of clinical safety and efficacy in the preparation of community herbal monographs for well-established and of community herbal monographs/ entries to the community list for traditional herbal medicinal products/substances/preparations [S/OL]. 2006- 09-07. http ://www.ema.europa.eu/doc s/en_GB/document_ library/Scientific_guideline/2009/O9AVCSOOOO3644.pdf.
  • 8European Medicines Agency. Uptake of the traditional use registration scheme and implementation of the provisions of directive 2004/24EC in EU Member States (revision 3) [S/OL]. 2013-05-08. http://www.ema.europa. eu/ docs/en_GB/ document library /Report/2011/0 5 /W C 500106706.pdf.
  • 9Commission of the European Communities. Communication from the Commission to the Council and the European Parliament concerning the report on the experience acquired as a result of the application of the provisions of Chapter 2a of Directive 2001/83/EC, as amended by Directive 2004/24/EC, on specific provisions applicable to traditional herbal medicinal products [S/OL]. 2008-09-29. http://eur-lex.europa.eu/legal-content/ EN/ALL/;j sessionid--v7ryT41Pcvv3pd2xM 1 tgJ3 QnHbdX- 1 ltVlbTjpDtlv2RTbnLCwyFH!- 1014547573?uri=CELEX: 52008DC0584.
  • 10Committee on Herbal Medicinal Products. Overview of assessment work-Priority list [S/OL]. 2013-11-22. http:// www.ema.europa.eu/docs/en_GB/document_library/Other/ 2009/12/WC500017724.pdf.

共引文献30

同被引文献43

引证文献6

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部